The pharma major beat analysts' expectations in the fourth quarter of 2024, despite looming competition for its top heart drug Entresto. The watchdog blocked access to DeepSeek after the companies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback